# Encore Medical, Inc. (EMI) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_10d389a0706ba0804433 · retrieved 2026-08-14T01:26:06.441Z

## Overview
Encore Medical, Inc. develops, manufactures, and markets septal occlusion devices for transcatheter closure of cardiac defects such as patent foramen ovale (PFO) and atrial septal defects (ASD); the company has obtained CE Mark approval and markets products in approximately 20 countries outside the United States, with approximately 35,000 implants to date, and is conducting FDA clinical trials to…

Encore Medical, Inc., a structural heart device company, is conducting an initial public offering of 3,000,000 shares of common stock at an assumed price of $5.00 per share, expected to raise approximately $15,000,000 in gross proceeds. The company has applied for listing on NYSE American under the symbol "EMI". Net proceeds, estimated at approximately $10,600,000 (or $12,670,000 if underwriters exercise their over-allotment option in full), will be used primarily to finance clinical trials for stroke and migraine indications, repay debt obligations, and support working capital and general corporate purposes. The offering is contingent upon listing approval on NYSE American.

## Terms
- Counterparty: Public investors · Deal value: $15.0M · Consideration: cash · Price/share: $5

## Key dates
- Announced 2026-08-10

## Timeline
- 2026-08-10 · S-1/A (0001104659-26-093252): S-1/A - Encore Medical, Inc. — *Encore Medical, Inc. develops, manufactures, and markets septal occlusion devices for transcatheter closure of cardiac defects such as patent foramen ovale (PFO) and atrial septal defects (ASD); the company has obtained CE Mark approval and markets products in approximately 20 countries outside the United States, with approximately 35,000 implants to date, and is conducting FDA clinical trials to…* Encore Medical, Inc., a structural heart device company, is conducting an initial public offering of 3,000,000 shares of common stock at an assumed price of $5.00 per share, expected to raise approximately $15,000,000 in gross proceeds. The company has applied for listing on NYSE American under the symbol "EMI". Net proceeds, estimated at approximately $10,600,000 (or $12,670,000 if underwriters exercise their over-allotment option in full), will be used primarily to finance clinical trials for stroke and migraine indications, repay debt obligations, and support working capital and general corporate purposes. The offering is contingent upon listing approval on NYSE American.
  https://www.sec.gov/Archives/edgar/data/1838003/0001104659-26-093252.txt

## Citations
- 0001104659-26-093252 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926093252